Announcements

We are pleased to announce that four new scholars have been appointed as Editorial Board Members (EBMs) of Current Oncology (ISSN 1718-7729). We wish our new members success in both their research and their efforts to develop the journal.

Further details about the Editorial Board of Current Oncology can be found at the following link: https://www.mdpi.com/journal/curroncol/editors.

Current Oncology is recruiting scholars from around the world to join our Editorial Board. To apply for membership or recommend potential candidates, please contact the Current Oncology Editorial Office and provide the following documents:

• A full academic CV;
• A short cover letter detailing interest in the position.

You may also contact the Current Oncology Editorial Office to request further information.

As part of our continued efforts to support impactful cancer research and foster scientific dialogue, MDPI is spotlighting gynecological cancer, a diverse group of malignancies affecting the female reproductive system, including the ovaries, uterus, cervix, and more. These cancers encompass a range of distinct diseases with varying biological characteristics, risk factors, and treatment approaches. Despite advances in screening, diagnosis, and therapy, gynecological cancers continue to present significant challenges in clinical management and patient care.

Gynecological cancers can affect individuals across different stages of life, with incidence and risk factors varying by cancer type. Cervical cancer, for example, is strongly associated with persistent infection with high-risk human papillomavirus (HPV), while endometrial cancer is more commonly diagnosed after menopause. Ovarian cancer remains particularly challenging due to its vague early symptoms and the lack of effective population-wide screening methods. According to the American Cancer Society, approximately 21,010 new cases of ovarian cancer, 13,490 new cases of cervical cancer, and 68,270 new cases of uterine cancer are expected to be diagnosed in the United States in 2026, highlighting the continued need for advances in prevention, early detection, and treatment.

By bringing together cutting-edge research and creating various focused Special Issues, MDPI journals aim to continue to facilitate knowledge exchange and highlight emerging advances in the field of gynecological oncology. These efforts play an important role in advancing innovation, improving early detection and therapeutic strategies, and ultimately enhancing outcomes for patients worldwide.

Invited speakers:
Prof. Dr. Jalid Sehouli, Charité—Universitätsmedizin, Germany	Dr. Barbara Guinn, University of Hull, UK	Dr. Michelle R. Dawson, Brown University, USA	Dr. Marion Curti, Mayo Clinic, USA	Dr. Giuseppe Gullo, Ospedali Riuniti Villa Sofia—Cervello (AORC), Italy

Register for this webinar for free here!

“Patient-Derived Microtumors: How Can We Continue to Personalize Treatment for Ovarian Cancer Patients?“
by Emily O’Brien, Dhruva Dave, Abbie Kleckley, Fibiana Oladipo, Christopher M. Mayer, Rebecca Henderson, Blanca Vasquez, Elizabeth Lucas, Jeffrey A. Thomas, Rony Thomas et al.
Targets 2026, 4(1), 2; https://doi.org/10.3390/targets4010002

“Targeted Biological Therapy and Germline Mutation Prevalence in Advanced Ovarian Cancer Patients“
by Anne-Marie Mosbæk Ellegaard, Tim Svenstrup Poulsen and Estrid Høgdall
Onco 2025, 5(4), 52; https://doi.org/10.3390/onco5040052

“Long-Term Outcomes of Co-Testing with 3-Type HPV mRNA (16/18/45) and Cytology in Women Under 40: A Real-World Cohort from Northern Norway (8–10 Years of Follow-Up)“
by Marie Bostrøm, Gunnar Skov Simonsen and Sveinung Wergeland Sørbye
Targets 2025, 3(4), 36; https://doi.org/10.3390/targets3040036

“Machine Learning Models for Predicting Gynecological Cancers: Advances, Challenges, and Future Directions“
by Pankaj Garg, Madhu Krishna, Prakash Kulkarni, David Horne, Ravi Salgia and Sharad S. Singhal
Cancers 2025, 17(17), 2799; https://doi.org/10.3390/cancers17172799

“The Role of Tissue Factor-Positive Microparticles in Gynecological Cancer-Associated Disseminated Intravascular Coagulation: Molecular Mechanisms and Clinical Implications“
by Muqaddas Qureshi, Muhammad Tanveer Alam and Ahsanullah Unar
Onco 2025, 5(3), 33; https://doi.org/10.3390/onco5030033

“Updated Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma: The Polish Society of Gynecological Oncology (2025v)“
by Jacek J. Sznurkowski, Lubomir Bodnar, Anna Dańska-Bidzińska, Andrzej Marszałek, Pawel Blecharz, Anita Chudecka-Głaz, Dagmara Klasa-Mazurkiewicz, Artur Kowalik, Agnieszka Zołciak-Siwinska, Aleksandra Zielinska et al.
Curr. Oncol. 2025, 32(6), 340; https://doi.org/10.3390/curroncol32060340

“Evaluating the Cost-Effectiveness of Cervical Cancer Screening and Treatment in Western Romania“
by Ion Petre, Șerban Mircea Negru, Florina Buleu, Radu Dumitru Moleriu, Marina Adriana Mercioni, Izabella Petre, Anca Bordianu, Vladiana Turi, Luciana Marc, Daian Ionel Popa et al.
Curr. Oncol. 2025, 32(6), 336; https://doi.org/10.3390/curroncol32060336

“Targeting Pathways and Mechanisms in Gynecological Cancer with Antioxidant and Anti-Inflammatory Phytochemical Drugs“
by Sandhya Shukla, Arvind Kumar Shukla, Navin Ray, Adarsha Mahendra Upadhyay, Fowzul Islam Fahad, Sayan Deb Dutta, Arulkumar Nagappan and Raj Kumar Mongre
Onco 2025, 5(2), 24; https://doi.org/10.3390/onco5020024

“Artificial Intelligence in Gynecological Oncology from Diagnosis to Surgery“
by Stefano Restaino, Maria Rita De Giorgio, Giulia Pellecchia, Martina Arcieri, Francesca Maria Vasta, Camilla Fedele, Paolo Bonome, Giuseppe Vizzielli, Sandro Pignata and Gaia Giannone
Cancers 2025, 17(7), 1060; https://doi.org/10.3390/cancers17071060

“From Genes to Clinical Practice: Exploring the Genomic Underpinnings of Endometrial Cancer“
by Thulo Molefi, Lloyd Mabonga, Rodney Hull, Motshedisi Sebitloane and Zodwa Dlamini
Cancers 2025, 17(2), 320; https://doi.org/10.3390/cancers17020320

“Gynecological Cancers: From Bench to Bedside“ Guest Editor: Prof. Dr. Francesco Cosentino Submission deadline: 30 October 2026	“2nd Edition: Action and Impact: Prevention and Screening Strategies Contributing to the Elimination of Cervical Cancer” Guest Editor: Dr. Samara Perez Submission deadline: 31 December 2026
“Improving the Quality of Life in Patients with Gynecological Cancer“ Guest Editor: Dr. Vasilios Pergialiotis Submission deadline: 20 January 2027	“Global Strategies and Equity Challenges in Cervical Cancer Prevention and Elimination“ Guest Editor: Dr. Simon M. Manga Submission deadline: 15 February 2027

To commemorate World Cancer Day 2026, MDPI is pleased to introduce the “World Cancer Day 2026 Webinar Series”. Reflecting the global theme “United by Unique”, this series highlights how every story, discovery, and voice contributes to strengthening the global fight against cancer.

In our August session, we welcome leading voices in ovarian cancer research to share impactful insights, raise awareness, and highlight recent advances in prevention, diagnosis, and treatment.

Through this series, we aim to empower the global community with knowledge, inspire collaboration, and support ongoing efforts to address cancer worldwide. Together, we honor every patient’s journey, recognize every researcher’s contribution, and reinforce the power of collective action in the fight against cancer.

Date: 31 August 2026
Time: 5:00 p.m. CEST | 11:00 a.m. EDT
Webinar ID: 865 6852 3905
Webinar Secretariat: webinar@mdpi.com
Website: https://sciforum.net/event/WCD2026-4

Register now for free!

Program:

After registering, you will receive a confirmation email outlining how to join this webinar. Registrations with academic institutional email addresses will be prioritized.

Unable to attend? Register anyway, and we will let you know when the recording is available to watch.

Webinar Speakers:

• Prof. Dr. Jalid Sehouli, Department of Gynecology, Charité – Universitätsmedizin Berlin, Germany;
• Dr. Barbara Guinn, Hull York Medical School, University of Hull, UK;
• Dr. Michelle R. Dawson, Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, USA;
• Dr. Marion Curtis, Department of Immunology, Mayo Clinic, USA;
• Dr. Giuseppe Gullo, Azienda Ospedaliera Ospedali Riuniti Villa Sofia – Cervello (AORC), University of Palermo, Italy.

Relevant Special Issues:

“Biomarkers for the Detection of Cancer and Monitoring Response to Treatment”
Guest Editor: Dr. Barbara Guinn
Deadline for manuscript submissions: 1 January 2027

“Fertility Preservation in Gynecological Cancer”
Guest Editors: Dr. Giuseppe Gullo and Dr. Luigi Della Corte
Deadline for manuscript submissions: 28 February 2027

In this issue, we had the pleasure of speaking with Dr. Costantino Errani, who is the member of Current Oncology’s Editorial Board. Dr. Errani joined the Editorial Board of Current Oncology (ISSN 1718-7729) in 2021. At present, as an Editorial Board Member, he actively contributes to the journal’s editorial activities and ensures the scientific rigor and quality of published manuscripts. Here, he will share his peer review experience, research interests, and academic journey.

Dr. Costantino Errani is an orthopaedic surgeon at the Rizzoli Orthopaedic Institute (Bologna, Italy). He is a dedicated surgeon specializing in the treatment and care of children and adults with bone and soft tissue tumors. His expertise encompasses treatment of patients with a range of rare primary musculoskeletal tumors, such as osteosarcoma and Ewing’s sarcoma, as well as patients with metastatic bone diseases, with expertise in limb-salvage surgery and complex biological and prosthetic reconstructions following tumor resection. He received his medical degree from the University of Bologna and completed his residency in Orthopaedics and Traumatology at the Rizzoli Orthopaedic Institute and subsequently earned a PhD in Oncology and Pathology, focusing on the molecular biology and genetic profiling of sarcomas. To further advance his expertise in musculoskeletal oncology, he underwent advanced clinical and research training at internationally renowned institutions, including Memorial Sloan Kettering Cancer Center (New York, USA), Mayo Clinic (Rochester, USA), and Karolinska Hospital (Stockholm, Sweden). Dr. Errani’s research interests include musculoskeletal oncology, sarcoma biology, skeletal metastases, prognostic biomarkers, and innovative reconstructive techniques following tumor surgery. He has served as Principal Investigator in numerous national and international clinical studies and has played a key role in developing multidisciplinary treatment pathways for patients with uncommon tumors and metastatic bone disease. His scientific contributions have significantly advanced the understanding of biology, prognosis, and surgical management of bone and soft tissue tumors. His surgical expertise includes a variety of complex limb-salvage techniques, using biologic, prosthetic, custom-designed implants, and advanced 3D technology. These strategies aim to optimize survival and restore patients to their highest level of function after surgery. An internationally recognized authority in orthopaedic oncology, Dr. Errani has performed more than 3000 surgical procedures, authored over 170 PubMed-indexed peer-reviewed publications, contributed to several book chapters, and delivered invited lectures at major international scientific meetings across Europe, North America, and Asia. He currently serves on the editorial boards of several international journals, including serving as Deputy Editor of the European Journal of Orthopaedic Surgery and Traumatology, and Associate Editor of BMC Musculoskeletal Disorders and Current Oncology.

The following is a short Q&A with Dr. Costantino Errani:

1. Could you briefly introduce your current research focus and any key projects you are working on?
I am an orthopaedic surgeon dedicated to the treatment of children and adults who have bone or soft tissue tumors located in the extremities, pelvis, and sacrum. My research involves understanding the molecular biology and the genetic profile of sarcomas and improving the durability and function of joint replacements.

2. You have been working on the Editorial Board of Current Oncology since 2021. How has your experience working with the journal been since then?
My experience as an editor at Current Oncology has been a pleasant surprise, as I have grown as an editor alongside the journal, which I have seen grow both in the number of articles submitted and in the quality of those articles.

3. As an academic editor, what aspects do you prioritize most when evaluating manuscripts? What advice would you give to authors preparing to submit their work to Current Oncology?
The priority is the novelty of the study’s topic, which should address a clinical question that no one has yet answered—an open question. Therefore, I advise authors to always ask themselves what their study adds to those published so far.

4. You are currently editing the Current Oncology Special Issue, “Advances in Surgical Treatment of Children with Bone Tumors”. From your perspective as a Guest Editor, what potential value do you think this Special Issue can bring to oncology research and clinical practice?
Studies should always be driven by a clinical need, and the surgical treatment of rare diseases such as pediatric sarcomas requires determining which treatments are most effective and how we can improve existing treatments by reducing short- and long-term complications.

5. As both an author and a member of the Editorial Board, do you have any suggestions or expectations for the journal’s future development?
My suggestion—and also my expectation—is that Current Oncology will increasingly strive in the near future to raise the quality of its articles by giving priority to those that address an unresolved clinical question using appropriate methodology.

6. Current Oncology is an open access journal. What impact do you think open access publishing has on your field?
Open access journals are certainly useful because they allow everyone—even those who cannot afford it—to stay up to date on scientific developments, and they also make researchers’ work more visible.

7. Finally, what is one piece of advice you would give to early career researchers?
Read scientific articles, study constantly, and continue clinical practice, or, if you are a basic researcher, find a clinician to collaborate with on research, since research usually stems from a clinical question posed by a patient that no one has yet answered.

We sincerely thank Dr. Errani for sharing his insights and perspectives with us. We greatly value the contributions of our Editorial Board Members to the continued development of Current Oncology and the advancement of high-quality oncology research. We hope this interview will provide valuable insights and inspiration to the oncology community.

A welcome message from the Chair:

The management of breast cancer continues to evolve rapidly, driven by advances in clinical research and emerging treatment options. Staying aligned with current evidence-based standards is essential to ensuring consistent, high-quality care across Canada.

Join us for a clinician-focused webinar exploring Canadian best practices and the National Clinical Consensus Recommendations developed by REAL Canadian Breast Cancer Alliance. These annually updated guidelines are produced through a structured, multidisciplinary process that integrates national expertise and the latest clinical trial evidence to support best practices in breast cancer care delivery.

This session will provide an overview of current consensus recommendations across key disease settings, including the following:

• HER2-positive breast cancer;
• HR-positive early-stage breast cancer;
• HR-positive advanced-stage breast cancer;
• Triple-negative breast cancer.

Participants will gain a clear understanding of how these recommendations translate into clinical practice and support standardized treatment decision-making across Canadian care settings. REAL Canadian Breast Cancer Alliance continues to release annual updates aimed at strengthening alignment in care pathways and improving outcomes through evidence-informed practice.

This webinar is intended for oncologists, surgeons, radiologists, pathologists, nurse practitioners, and other healthcare professionals involved in breast cancer care.

Date: 3 September 2026, 6:00 p.m. EDT | 11:00 p.m. CEST
Webinar ID: 899 2749 6179

Register now for free!

Program:

After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with email addresses from academic institutions will be prioritized.

Unable to attend? Register anyway and we will let you know when the recording is available for viewing.

Webinar Chair and Keynote Speakers:

• Dr. Mita Manna, Saskatoon Cancer Centre, University of Saskatchewan, Canada;
• Dr. Nathalie Levasseur, BC Cancer—Vancouver, University of British Columbia, Canada;
• Dr. Katarzyna J. Jerzak, Sunnybrook Odette Cancer Centre, University of Toronto, Canada.

In September 2025, the journal Current Oncology (ISSN 1718-7729) collaborated with REAL Canadian Breast Cancer Alliance to release a Special Issue to provide guidance to physicians, other health care professionals, and policy makers for improving outcomes for patients with breast cancer across Canada.

Special Issue:

“REAL Canadian Breast Cancer Alliance Collection”
Guest Editors: Dr. Katarzyna J. Jerzak, Dr. Nathalie LeVasseur, Dr. Nathaniel Bouganim and Dr. Mita Manna
Deadline for manuscript submissions: 31 December 2026

We are honored to interview Dr. Mita Manna, Chair of REAL Canadian Breast Cancer Alliance and Guest Editor of this Special Issue. In this interview, she shares insights into its vision, impact on clinical practice and policy, and the key challenges and opportunities shaping the future of breast cancer care in Canada and beyond.

The following is an interview with Dr. Mita Manna:

We sincerely thank Dr. Mita Manna for sharing her valuable insights with us. We also invite our readers to follow this Special Issue to learn more about the future consensus statements and recommendations proposed by REAL Canadian Breast Cancer Alliance to advance breast cancer research, treatment, and patient care.

We are pleased to present an interview with Dr. Fernando Munoz, a valued contributor to Current Oncology (ISSN 1718-7729) since 2023. As a Guest Editor for multiple Special Issues and an Editor for Special Issue reprints, Dr. Munoz has actively contributed to the journal’s academic community. In this interview, he will share his perspectives on Special Issue development, his research interests, and the experiences that have shaped his academic career.

Dr. Fernando Munoz’s related Special Issues:

• “Evolution of Treatments of Prostate Cancer: From Biology to Current Advanced Technologies”;
• “The Evolving Landscape of Precision Medicine in Radiation Oncology”.

The following is an interview with Dr. Fernando Munoz:

1. Could you briefly introduce yourself and your current research interests?
I am a radiation oncologist with extensive clinical experience, with a particular interest in genitourinary, gastrointestinal, and head and neck malignancies.
Although I was born and raised in Madrid, Spain, following the completion of my specialization in radiation oncology, I moved to northern Italy for personal reasons and have since built my entire professional career in Turin. Over the years, Turin has become both my professional and personal home, where I have developed my clinical expertise and continued to grow as a radiation oncologist.

2. Could you share your experience as a Guest Editor for Current Oncology? What was your overall experience in organizing and coordinating the Special Issue?
My experience as a Guest Editor for Current Oncology was excellent throughout the entire process. I found the experience both rewarding and professionally enriching.
I would particularly like to acknowledge the support of the Special Issue Editor, who accompanied and guided me throughout the process. She was precise, meticulous, demanding, and highly knowledgeable, and I truly appreciated these qualities. I believe these are exactly the characteristics we need when undertaking a project of this kind, as they help maintain high standards and ensure that every aspect of the process is handled carefully and efficiently.
As clinicians, our demanding daily commitments can sometimes lead us to postpone or delay responses, despite our best intentions. Having someone who is attentive, organized, and persistent in following up is therefore extremely valuable. The Editor’s professionalism and dedication were instrumental in keeping the process on track, and I am very grateful for her support throughout the entire Special Issue.

3. Following the publication of the first Special Issue Reprints, are there any emerging areas or frontier topics that you believe deserve more attention in future research and Special Issues?
I do not believe that there are any specific emerging areas that stand out at this stage. Rather, I believe that precision medicine in oncology will be the major driving force for the future of cancer care. It will guide and increasingly personalize our diagnostic and therapeutic approaches, opening the door to more individualized treatment strategies and, ultimately, to truly personalized cancer care across the field of oncology.

4. In your view, what are the most important characteristics of a high-quality manuscript?
In my view, a high-quality manuscript should first and foremost address a clear, relevant, and scientifically meaningful question. From a reviewer’s perspective, scientific rigor is essential: the study design should be appropriate to the research question, the methodology should be robust and transparently described, and the statistical analysis should be sound and appropriate.
I also consider originality and added value to be important, although novelty should not come at the expense of methodological quality. Equally important is the consistency between the study objectives, the results, and the conclusions. Authors should interpret their findings critically and avoid conclusions that go beyond what the data can actually support.
Finally, I believe that a strong manuscript should clearly acknowledge its limitations and potential sources of bias, while presenting the findings in a clear and simple way, as well as in a balanced, and clinically meaningful way. In oncology in particular, the ultimate value of a manuscript lies in its ability to contribute to a better understanding of disease and, whenever possible, to improve or inform clinical practice and future research.

5. As a Guest Editor, what advice would you give to authors preparing to submit their work to your Special Issue?
My advice to authors preparing to submit their work to a Special Issue would be to focus first and foremost on the scientific quality and clinical relevance of their research. A strong manuscript should address a clear and meaningful question, be supported by a rigorous methodology, and provide results that genuinely add something to the existing literature.
I would also encourage authors to present their work in a clear and balanced manner, ensuring that the conclusions are fully supported by the data and that the limitations of the study are openly discussed. In my experience as a reviewer and Guest Editor, transparency and methodological rigor are just as important as novelty.
Finally, I would encourage authors to carefully consider the existing literature and clearly explain how their work contributes to the field. A Special Issue is an opportunity not only to present new findings, but also to stimulate discussion and provide insights that may be useful for future research and, ultimately, for clinical practice.

6. What advice would you give to researchers who are interested in serving as Guest Editors and contributing to academic publishing?
I would encourage young researchers to actively engage with the scientific community and to make themselves visible through the quality of their work. Serving as a Guest Editor is a valuable opportunity to develop scientific leadership, build collaborations, and contribute to the advancement of the field.
My advice is to be proactive: publish high-quality research, participate in peer review, attend scientific meetings, collaborate internationally, and do not hesitate to accept responsibilities that allow you to demonstrate your expertise. Visibility in academia is built progressively through credibility, consistency, and a genuine willingness to contribute.
Above all, young researchers should remember that academic recognition follows from the quality and impact of their contribution to the scientific community.

7. Outside of your busy research work, how do you maintain a healthy work–life balance?
I try to maintain a balance between my professional and personal life—which is not always easy. Whenever possible, I enjoy traveling and staying active through sport. I also make time for reading and for maintaining a rich social life, as I believe that continuing to learn and engaging with people and different cultures are important not only for personal well-being, but also for maintaining an open and creative perspective in my professional life.

8. How do you view the development of open access publishing in the academic community? What opportunities and challenges do you think open access brings to researchers and the scientific publishing landscape?
I believe that the major advantage of open access publishing is that it provides students, young physicians, and early-career researchers with immediate and easy access to scientific knowledge. This can significantly facilitate education, collaboration, and the dissemination of research.
The main challenge, however, is the financial burden associated with publication. Researchers do not always have sufficient support from their universities or academic institutions, particularly now in Europe, and research funding and institutional resources are becoming increasingly limited. In my view, this represents one of the most important challenges facing the open access model today.

We sincerely thank Dr. Fernando Munoz for sharing his valuable insights and experiences with us. We hope that this interview will provide readers with a deeper understanding of Special Issue development, research trends, and the experiences of scholars contributing to the advancement of prostate cancer research.

Conference: IASLC 2026 World Conference on Lung Cancer
Booth Number: 706
Date: 12–15 September 2026
Location: COEX, Seoul, Republic of Korea

The International Association for the Study of Lung Cancer (IASLC) is a globally recognized medical society dedicated to advancing research, education, and collaboration in lung cancer and thoracic malignancies.

Taking place in Seoul from 12 to 15 September 2026, the IASLC 2026 World Conference on Lung Cancer (WCLC 2026) will serve as a premier international forum for researchers, clinicians, and healthcare professionals to present the latest scientific discoveries, exchange innovative treatment strategies, and foster collaborations aimed at advancing the fight against lung cancer.

MDPI is excited to join WCLC 2026 as an exhibitor. We warmly invite attendees to visit our booth to discuss their latest research and learn how we can empower your scholarly journey through dedicated publishing services.

The following MDPI journals will be represented at the conference:

• Cancers;
• Current Oncology;
• Advances in Respiratory Medicine;
• BioMed;
• Clinics and Practice;
• Diagnostics;
• Journal of Clinical Medicine;
• Journal of Respiration;
• Pharmaceuticals;
• Precision Oncology;
• Surgical Techniques Development;
• Onco;
• Radiation;
• Targets.

Visit our booth to connect with our team and get your questions answered in person! Find more details about the event on the conference website.